NewsTradingSentimentCalendarCommunityBriefing
Stocks

Broadcom's AI Chip Growth Outpaces Stock Performance

By Stocks Desk · 2026-09-13 · 2 min read
A close-up view of a complex silicon wafer with intricate circuit patterns
Illustration: Tradingbird

Broadcom delivered 86% revenue growth in fiscal Q3, yet the stock lagged the sector as guidance missed consensus. Management projects AI revenue to double by fiscal 2027.

Broadcom reported fiscal 2026 third-quarter revenue of $29.6 billion, an 86% year-over-year increase driven by demand for custom AI chips and networking processors. Non-GAAP earnings per share nearly doubled to $3.32. Despite these figures, the stock underperformed the PHLX Semiconductor Sector index, which rose 97% over the past year, because the company’s fourth-quarter guidance of $34.8 billion fell short of the $35.1 billion Wall Street expected.

The divergence between operational results and market valuation highlights a specific disconnect in how investors are pricing Broadcom’s AI infrastructure business. While the PHLX Semiconductor Sector index surged, Broadcom remained flat, creating a valuation gap that some analysts attribute to short-term guidance misses rather than long-term structural issues. The company’s core ASIC and networking components continue to see robust uptake in AI data centers, suggesting the current stock price may not fully reflect the underlying demand trajectory.

AI Revenue Accelerates Rapidly

Broadcom’s AI chip revenue expanded by 221% in the third quarter to reach $16.7 billion. For the current quarter, the company anticipates a 236% year-over-year increase, projecting AI revenue of $21.7 billion. This segment now constitutes a significant portion of the total business, with overall fiscal 2026 AI revenue expected to hit $57.6 billion, an 186% increase from the prior year. The rapid scaling indicates that AI workloads are becoming the primary driver of Broadcom’s top-line growth.

Long-Term Projections Exceed Expectations

Management has outlined a multi-year growth path that extends beyond the current fiscal cycle. Broadcom estimates AI revenue will double to $115 billion in fiscal 2027 and reach $230 billion in fiscal 2028. On the recent earnings call, executives confirmed that supply chains are secured to meet the fiscal 2028 outlook. Additionally, the company projects earnings per share will exceed $30.00 in fiscal 2028, signaling confidence in sustained profitability as AI infrastructure spending continues to rise.

Industry Spending Context Remains Strong

Broadcom’s growth aligns with broader industry trends in capital expenditure. Nvidia recently estimated that the combined capital spending of the top five hyperscalers will reach $800 billion in 2026 and potentially $1.3 trillion in 2027. Total AI capital expenditure is projected to grow to between $3 trillion and $4 trillion by 2030. This macro environment supports Broadcom’s demand for custom silicon, as major tech firms continue to invest heavily in building out their AI infrastructure capabilities.

Based on reporting by The Globe and Mail, compiled by the Tradingbird desk.

More from the Stocks desk

All desk stories
  • A metallic turbocharger compressor wheel resting on a dark workbench
    Illustration: Tradingbird

    Garrett Motion Valuation Gap Amid Mixed Price Action

    Garrett Motion trades at a discount to consensus fair value despite recent quarterly declines, driven by a divergence between current earnings multiples and long-term margin expectations.

    2026-09-13
  • A modern hotel lobby with high ceilings and comfortable seating
    Illustration: Tradingbird

    Pebblebrook Hotel Trust Sets October Earnings Date

    Pebblebrook Hotel Trust has scheduled its Q3 2026 results for October 29, maintaining a valuation narrative driven by major urban event pipelines despite recent short-term price softness.

    2026-09-13
  • A clear glass vial standing on a white laboratory bench.
    Illustration: Tradingbird

    ADMA Biologics Faces Earnings Test Amid Share Price Slump

    ADMA Biologics shares have dropped significantly year-to-date, falling 48.4% despite a 20% boost in immunoglobulin output. With a forward P/E of 12.09, the market is currently pricing in caution ahead of the upcoming earnings report.

    2026-09-13